Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gilead Sciences
Biotech
Gilead pays $43.5M for Xilio's early-phase IL-12 prospect
Gilead is bucking the trend in IL-12, entering the space after seeing rivals such as AstraZeneca and Bristol Myers Squibb retreat from the cytokine.
Nick Paul Taylor
Mar 28, 2024 8:08am
Merck-Gilead's weekly HIV combo maintains viral suppression
Mar 6, 2024 11:08am
Gilead bets $1.5B-plus on Merus' trispecifc T-cell engagers
Mar 6, 2024 10:02am
CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer
Feb 26, 2024 10:49am
AbbVie names CEO successor—Chutes & Ladders
Feb 23, 2024 9:30am
Gilead pauses CD47 solid tumor trials as FDA seeks partial hold
Feb 16, 2024 6:45am